StoxAster DM Quality Care vs Gland Pharma: share price & financials comparison
NSE: ASTERDM vs GLAND · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Aster DM Quality Care vs Gland Pharma at a glance
Aster DM Quality Care (ASTERDM) has a market capitalisation of ₹62,979 Cr, against ₹55,016 Cr for Gland Pharma (GLAND). Over the past year Gland Pharma has returned +74.4%, compared with +4.9% for Aster DM Quality Care. On valuation, Gland Pharma trades at a lower P/E of 44.5 versus 133.8. Gland Pharma earns a higher return on equity (11.6% vs 6.0%). Aster DM Quality Care comes out ahead on growth. Gland Pharma comes out ahead on size, valuation, profitability, financial health, momentum and technicals. Across the scored metrics below, Aster DM Quality Care leads on 4 and Gland Pharma on 13. On StoxGud's 10-point checklist, Aster DM Quality Care scores 5/10 and Gland Pharma scores 8/10.
| Metric | Aster DM Quality Care | Gland Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹62,979 Cr | ₹55,016 Cr |
| Revenue (latest FY) | ₹4,643 Cr | ₹6,431 Cr |
| Net profit (latest FY) | ₹388 Cr | ₹1,027 Cr |
| Valuation | ||
| P/E | 133.8 | 44.5 |
| P/B | 8.08 | 5.15 |
| Dividend yield | 0.09% | 0.54% |
| Profitability | ||
| Return on equity | 6.0% | 11.6% |
| Net profit margin | 7.2% | 17.5% |
| Operating margin | 21.1% | 27.2% |
| Growth | ||
| Revenue growth (YoY) | +136.3% | +23.3% |
| Net profit growth (YoY) | +138.2% | +58.3% |
| Revenue CAGR (multi-year) | -11.6% | +13.2% |
| Financial health | ||
| Debt to equity | 0.51 | 0.02 |
| Momentum | ||
| 1-month return | +4.7% | +7.9% |
| 1-year return | +4.9% | +74.4% |
| 3-year CAGR | +28.3% | +27.0% |
| 5-year CAGR | +28.4% | -1.7% |
| Distance from 52W high | -16.9% | +0.0% |
| Technicals | ||
| RSI (14) | 76 | 88 |
| Price vs 200-day avg | +0.5% | +42.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Aster DM Quality Care | Gland Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 5/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Aster DM Quality Care or Gland Pharma?
Aster DM Quality Care has a market cap of ₹62,979 Cr and Gland Pharma has a market cap of ₹55,016 Cr as of 13 Nov 2026.
Which has a lower P/E, Aster DM Quality Care or Gland Pharma?
Gland Pharma has the lower P/E: Aster DM Quality Care trades at 133.8 and Gland Pharma at 44.5.
Which gave better returns in the last year, Aster DM Quality Care or Gland Pharma?
Gland Pharma did better: Aster DM Quality Care returned +4.9% and Gland Pharma returned +74.4% over one year.
What is the difference between Aster DM Quality Care and Gland Pharma?
Both are NSE-listed companies in Healthcare. They are about the same size by market cap (₹62,979 Cr vs ₹55,016 Cr). In the latest financial year Aster DM Quality Care reported revenue of ₹4,643 Cr and Gland Pharma ₹6,431 Cr. Operating margin is 21.1% for Aster DM Quality Care and 27.2% for Gland Pharma. Debt to equity is 0.51 for Aster DM Quality Care and 0.02 for Gland Pharma.
Which is better, Aster DM Quality Care or Gland Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Aster DM Quality Care leads on 4 and Gland Pharma on 13. Aster DM Quality Care is ahead on growth. Gland Pharma is ahead on size, valuation, profitability, financial health, momentum and technicals. On StoxGud's rules-based checklist Aster DM Quality Care scores 5/10 and Gland Pharma scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.